198 related articles for article (PubMed ID: 26942068)
1. Favorable overall survival in stage III melanoma patients after adjuvant dendritic cell vaccination.
Bol KF; Aarntzen EH; Hout FE; Schreibelt G; Creemers JH; Lesterhuis WJ; Gerritsen WR; Grunhagen DJ; Verhoef C; Punt CJ; Bonenkamp JJ; de Wilt JH; Figdor CG; de Vries IJ
Oncoimmunology; 2016; 5(1):e1057673. PubMed ID: 26942068
[TBL] [Abstract][Full Text] [Related]
2. Adjuvant dendritic cell vaccination induces tumor-specific immune responses in the majority of stage III melanoma patients.
Boudewijns S; Bol KF; Schreibelt G; Westdorp H; Textor JC; van Rossum MM; Scharenborg NM; de Boer AJ; van de Rakt MW; Pots JM; van Oorschot TG; Duiveman-de Boer T; Olde Nordkamp MA; van Meeteren WS; van der Graaf WT; Bonenkamp JJ; de Wilt JH; Aarntzen EH; Punt CJ; Gerritsen WR; Figdor CG; de Vries IJ
Oncoimmunology; 2016 Jul; 5(7):e1191732. PubMed ID: 27622047
[TBL] [Abstract][Full Text] [Related]
3. Vaccination with mRNA-electroporated dendritic cells induces robust tumor antigen-specific CD4+ and CD8+ T cells responses in stage III and IV melanoma patients.
Aarntzen EH; Schreibelt G; Bol K; Lesterhuis WJ; Croockewit AJ; de Wilt JH; van Rossum MM; Blokx WA; Jacobs JF; Duiveman-de Boer T; Schuurhuis DH; Mus R; Thielemans K; de Vries IJ; Figdor CG; Punt CJ; Adema GJ
Clin Cancer Res; 2012 Oct; 18(19):5460-70. PubMed ID: 22896657
[TBL] [Abstract][Full Text] [Related]
4. Autologous monocyte-derived DC vaccination combined with cisplatin in stage III and IV melanoma patients: a prospective, randomized phase 2 trial.
Boudewijns S; Bloemendal M; de Haas N; Westdorp H; Bol KF; Schreibelt G; Aarntzen EHJG; Lesterhuis WJ; Gorris MAJ; Croockewit A; van der Woude LL; van Rossum MM; Welzen M; de Goede A; Hato SV; van der Graaf WTA; Punt CJA; Koornstra RHT; Gerritsen WR; Figdor CG; de Vries IJM
Cancer Immunol Immunother; 2020 Mar; 69(3):477-488. PubMed ID: 31980913
[TBL] [Abstract][Full Text] [Related]
5. Ipilimumab administered to metastatic melanoma patients who progressed after dendritic cell vaccination.
Boudewijns S; Koornstra RH; Westdorp H; Schreibelt G; van den Eertwegh AJ; Geukes Foppen MH; Haanen JB; de Vries IJ; Figdor CG; Bol KF; Gerritsen WR
Oncoimmunology; 2016 Aug; 5(8):e1201625. PubMed ID: 27622070
[TBL] [Abstract][Full Text] [Related]
6. Response and survival of metastatic melanoma patients treated with immune checkpoint inhibition for recurrent disease on adjuvant dendritic cell vaccination.
van Willigen WW; Bloemendal M; Boers-Sonderen MJ; de Groot JWB; Koornstra RHT; van der Veldt AAM; Haanen JBAG; Boudewijns S; Schreibelt G; Gerritsen WR; de Vries IJM; Bol KF
Oncoimmunology; 2020 Mar; 9(1):1738814. PubMed ID: 33457087
[TBL] [Abstract][Full Text] [Related]
7. Route of administration modulates the induction of dendritic cell vaccine-induced antigen-specific T cells in advanced melanoma patients.
Lesterhuis WJ; de Vries IJ; Schreibelt G; Lambeck AJ; Aarntzen EH; Jacobs JF; Scharenborg NM; van de Rakt MW; de Boer AJ; Croockewit S; van Rossum MM; Mus R; Oyen WJ; Boerman OC; Lucas S; Adema GJ; Punt CJ; Figdor CG
Clin Cancer Res; 2011 Sep; 17(17):5725-35. PubMed ID: 21771874
[TBL] [Abstract][Full Text] [Related]
8. Prolonged survival of patients receiving active immunotherapy with Canvaxin therapeutic polyvalent vaccine after complete resection of melanoma metastatic to regional lymph nodes.
Morton DL; Hsueh EC; Essner R; Foshag LJ; O'Day SJ; Bilchik A; Gupta RK; Hoon DS; Ravindranath M; Nizze JA; Gammon G; Wanek LA; Wang HJ; Elashoff RM
Ann Surg; 2002 Oct; 236(4):438-48; discussion 448-9. PubMed ID: 12368672
[TBL] [Abstract][Full Text] [Related]
9. Clinical and immunologic results of a randomized phase II trial of vaccination using four melanoma peptides either administered in granulocyte-macrophage colony-stimulating factor in adjuvant or pulsed on dendritic cells.
Slingluff CL; Petroni GR; Yamshchikov GV; Barnd DL; Eastham S; Galavotti H; Patterson JW; Deacon DH; Hibbitts S; Teates D; Neese PY; Grosh WW; Chianese-Bullock KA; Woodson EM; Wiernasz CJ; Merrill P; Gibson J; Ross M; Engelhard VH
J Clin Oncol; 2003 Nov; 21(21):4016-26. PubMed ID: 14581425
[TBL] [Abstract][Full Text] [Related]
10. Complementary vaccination protocol with dendritic cells pulsed with autologous tumour lysate in patients with resected stage III or IV melanoma: protocol for a phase II randomised trial (ACDC Adjuvant Trial).
Ridolfi L; de Rosa F; Fiammenghi L; Petrini M; Granato AM; Ancarani V; Pancisi E; Soldati V; Cassan S; Bulgarelli J; Riccobon A; Gentili G; Nanni O; Framarini M; Tauceri F; Guidoboni M
BMJ Open; 2018 Aug; 8(8):e021701. PubMed ID: 30082356
[TBL] [Abstract][Full Text] [Related]
11. Patterns of recurrence in patients with melanoma after radical lymph node dissection.
Nathansohn N; Schachter J; Gutman H
Arch Surg; 2005 Dec; 140(12):1172-7. PubMed ID: 16365238
[TBL] [Abstract][Full Text] [Related]
12. Skin-test infiltrating lymphocytes early predict clinical outcome of dendritic cell-based vaccination in metastatic melanoma.
Aarntzen EH; Bol K; Schreibelt G; Jacobs JF; Lesterhuis WJ; Van Rossum MM; Adema GJ; Figdor CG; Punt CJ; De Vries IJ
Cancer Res; 2012 Dec; 72(23):6102-10. PubMed ID: 23010076
[TBL] [Abstract][Full Text] [Related]
13. Dendritic Cell Vaccination in Metastatic Melanoma Turns "Non-T Cell Inflamed" Into "T-Cell Inflamed" Tumors.
Bulgarelli J; Tazzari M; Granato AM; Ridolfi L; Maiocchi S; de Rosa F; Petrini M; Pancisi E; Gentili G; Vergani B; Piccinini F; Carbonaro A; Leone BE; Foschi G; Ancarani V; Framarini M; Guidoboni M
Front Immunol; 2019; 10():2353. PubMed ID: 31649669
[TBL] [Abstract][Full Text] [Related]
14. Adjuvant therapy of malignant melanoma and the role of sentinel node mapping.
Eggermont AM
Recent Results Cancer Res; 2000; 157():178-89. PubMed ID: 10857171
[TBL] [Abstract][Full Text] [Related]
15. HEV-associated dendritic cells are observed in metastatic tumor-draining lymph nodes of cutaneous melanoma patients with longer distant metastasis-free survival after adjuvant immunotherapy.
Bravo AI; Aris M; Panouillot M; Porto M; Dieu-Nosjean MC; Teillaud JL; Barrio MM; Mordoh J
Front Immunol; 2023; 14():1231734. PubMed ID: 37691949
[TBL] [Abstract][Full Text] [Related]
16. Prophylactic vaccines are potent activators of monocyte-derived dendritic cells and drive effective anti-tumor responses in melanoma patients at the cost of toxicity.
Bol KF; Aarntzen EH; Pots JM; Olde Nordkamp MA; van de Rakt MW; Scharenborg NM; de Boer AJ; van Oorschot TG; Croockewit SA; Blokx WA; Oyen WJ; Boerman OC; Mus RD; van Rossum MM; van der Graaf CA; Punt CJ; Adema GJ; Figdor CG; de Vries IJ; Schreibelt G
Cancer Immunol Immunother; 2016 Mar; 65(3):327-39. PubMed ID: 26861670
[TBL] [Abstract][Full Text] [Related]
17. Immunological responses to adjuvant vaccination with combined CD1c
Bloemendal M; Bol KF; Boudewijns S; Gorris MAJ; de Wilt JHW; Croockewit SAJ; van Rossum MM; de Goede AL; Petry K; Koornstra RHT; Figdor C; Gerritsen WR; Schreibelt G; de Vries IJM
Oncoimmunology; 2022; 11(1):2015113. PubMed ID: 36524210
[TBL] [Abstract][Full Text] [Related]
18. Therapeutic vaccination with an autologous mRNA electroporated dendritic cell vaccine in patients with advanced melanoma.
Wilgenhof S; Van Nuffel AM; Corthals J; Heirman C; Tuyaerts S; Benteyn D; De Coninck A; Van Riet I; Verfaillie G; Vandeloo J; Bonehill A; Thielemans K; Neyns B
J Immunother; 2011 Jun; 34(5):448-56. PubMed ID: 21577140
[TBL] [Abstract][Full Text] [Related]
19. Long overall survival after dendritic cell vaccination in metastatic uveal melanoma patients.
Bol KF; Mensink HW; Aarntzen EH; Schreibelt G; Keunen JE; Coulie PG; de Klein A; Punt CJ; Paridaens D; Figdor CG; de Vries IJ
Am J Ophthalmol; 2014 Nov; 158(5):939-47. PubMed ID: 25038326
[TBL] [Abstract][Full Text] [Related]
20. Dendritic cell vaccination in melanoma patients: From promising results to future perspectives.
Boudewijns S; Bloemendal M; Gerritsen WR; de Vries IJ; Schreibelt G
Hum Vaccin Immunother; 2016 Oct; 12(10):2523-2528. PubMed ID: 27322496
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]